[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346773-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346773-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-applications-of-pet-imaging-for-evaluating-treatment-induced-vascular-toxicity-in-oncology-review","Clinical applications of PET imaging for evaluating treatment-induced vascular toxicity in oncology - review","","Vascular toxicity arising from cancer and its treatments remains incompletely defined and often lacks targeted management. This review summarizes ongoing advances in using positron emission tomography (PET) to noninvasively characterize cancer-associated vascular toxicity. It also discusses how PET may provide prognostic information for predicting adverse cardiovascular outcomes in patients with cancer. Clinical investigations increasingly apply PET to assess vascular inflammation or toxicity during or after therapies such as chemotherapy, immune checkpoint inhibitors, and radiation therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-applications-of-pet-imaging-for-evaluating-treatment-induced-vascular-toxicity-in-oncology-review/346773/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-applications-of-pet-imaging-for-evaluating-treatment-induced-vascular-toxicity-in-oncology-review/346773.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the review focus on?","Question",{"text":63,"@type":64},"The review focuses on vascular toxicity caused by cancer and its treatments, noting that it remains largely uncharacterized and minimally treated.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is PET used to evaluate vascular toxicity in oncology?",{"text":68,"@type":64},"PET enables noninvasive characterization by assessing vascular inflammation/toxicity and supporting quantitative evaluation of physiological parameters using targeted radionuclides.",{"name":70,"@type":61,"acceptedAnswer":71},"Which PET radiotracer is most commonly used and what does it indicate?",{"text":72,"@type":64},"Fluorine-18-fluorodeoxyglucose is widely used and has shown promising associations with disease severity and clinical outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346773,1790146083,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","REVIEW  \nUPRI RNIENTON Clinical applications of PET imaging for evaluating  \ntreatment-induced vascular toxicity in oncology  \nAnjana Jayaramana and Mitchel R. Stacya,b,c  \nPurpose of review  \nVascular toxicity resulting from cancer and its treatment remains a largely uncharacterized and minimally treated pathology. This review highlights ongoing developments and applications of PET imaging for noninvasive characterization of cancer-associated vascular toxicity and discusses the potential prognostic value of PET imaging for predicting adverse cardiovascular outcomes in patients with cancer.  \nRecent findings  \nNumerous clinical investigations have used PET imaging to evaluate vascular inflammation/toxicity inpatients undergoing or completing cancer therapies, including chemotherapy, immune checkpoint inhibitors, and radiation therapy. The most widely utilized PET radionuclide for noninvasively detecting vascular toxicity in clinical oncology has been fluorine-18-fluorodeoxyglucose, which has demonstrated promising associations with disease severity and clinical outcomes. Emerging radionuclides continue to be developed for targeting immune cells and may increase the sensitivity and specificity of PET imaging for detecting vascular toxicity associated with cancers and their treatment.  \nSummary  \nThe use of PET imaging for noninvasive detection and quantification of cancer treatment-associated vascular toxicity continues to evolve and could provide a unique approach for predicting risk of adverse cardiovascular outcomes in various forms of cancer and treatment.  \nKeywords  \nchemotherapy, inflammation, nuclear imaging, oncology, positron emission tomography, vascular toxicity  \nINTRODUCTION  \nThe impact of anticancer therapies on the development of cardiotoxicity has been well characterized using imaging modalities such as echocardiography [1]; however, there remains a lack of comprehensive reports on the use of noninvasive imaging techniques to specifically detect, quantify, and predict vascular toxicity induced by cancer and therapeutic strategies for cancer. PET is the primary nuclear medicine imaging modality used for cancer diagnosis and monitoring and allows for quantitative assessment of various physiological parameters such as organ perfusion and tumor metabolism through the use and imaging of targeted radionuclides [2] . This review provides an overview of the processes underlying healthy vascular function, describes the mechanisms by which cancer therapies induce vascular toxicity and related complications such as venous thromboembolism (VTE), and summarizes the clinical studies to date that have incorporated PET imaging for noninvasive assessment of vascular toxicity in patients with cancer.  \nPATHOGENESIS AND MANIFESTATIONS OF CANCER THERAPY ASSOCIATED VASCULAR TOXICITY  \nMany cancer-targeting chemotherapies have been known to induce vascular dysfunction in patients,  \naCenter for Regenerative Medicine, Research Institute at Nationwide Children's Hospital, bInterdisciplinary Biophysics Graduate Program, The Ohio State University and cDivision of Vascular Diseases and Surgery, Department of Surgery, The Ohio State University College of Medicine, Columbus, Ohio, USA  \nCorrespondence to Mitchel R. Stacy, PhD, Division of Vascular Diseases & Surgery, The Ohio State University College of Medicine, Center for Regenerative Medicine, Research Institute at Nationwide Children's Hospital, 575 Children's Crossroad, WB4133, Columbus, OH 43215, USA. Tel: +1 614 355 5836; fax: +1 614 355 5726; e-mail: mitchel. [stacy@nationwidechildrens.org](stacy@nationwidechildrens.org)  \nCurr Opin Hematol 2026, 33:121–127  \nDOI:10.1097/MOH.0000000000000912  \nThis is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercia","cbCaik9Cfb49Yv7i","https://ap.wps.com/l/cbCaik9Cfb49Yv7i","pdf",636093,"English","# Purpose of review\n# Recent findings\n# Summary\n# Introduction\n# Pathogenesis and manifestations of cancer therapy associated vascular toxicity","[{\"question\":\"What clinical problem does the review focus on?\",\"answer\":\"The review focuses on vascular toxicity caused by cancer and its treatments, noting that it remains largely uncharacterized and minimally treated.\"},{\"question\":\"How is PET used to evaluate vascular toxicity in oncology?\",\"answer\":\"PET enables noninvasive characterization by assessing vascular inflammation/toxicity and supporting quantitative evaluation of physiological parameters using targeted radionuclides.\"},{\"question\":\"Which PET radiotracer is most commonly used and what does it indicate?\",\"answer\":\"Fluorine-18-fluorodeoxyglucose is widely used and has shown promising associations with disease severity and clinical outcomes.\"}]","Clinical applications of PET imaging for evaluating treatment-induced vascular toxicity in oncology - review | PDF",1790062683,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ecc709c1ec8cf70e5c508ad63eb851e.webp",983,1302,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e716fe87ff3e8beb98f00ad170f485d.webp",982,1301,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95c8638415acb790df1df7e56ece386c.webp",981,1300,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99ef90e40aae027321939d389610c2c0.webp",980,1299]